Login Register Cart 0
Generic placeholder image

当代阿耳茨海默病研究

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

CSF p-tau181 /Aβ42比值在阿尔茨海默氏痴呆症的鉴别诊断中提供了良好的“体内”准确性

卷 16, 期 7, 2019

页: [587 - 595] 页: 9

弟呕挨: 10.2174/1567205016666190725150836

价格: $65

摘要

背景：针对阿尔茨海默氏病（AD）的新的疾病缓解疗法需要可靠的诊断标记，才能正确招募全世界的患者。CSF AD生物标志物，即淀粉样蛋白-β42（Aβ42），总tau（t-tau）和苏氨酸181磷酸化的tau（p-tau181），在检测AD病理学方面显示出良好的诊断准确性，但在日常临床实践中是否真正有用仍然是一个辩论的问题。因此，需要在复杂的临床环境（即患有不同类型痴呆症的患者）中进行进一步验证，以支持他们将来在全球范围内的采用。 方法：我们在526例患有痴呆症临床诊断的患者（277例AD和249例其他类型的痴呆，OTD）中测量了CSF AD生物标志物的浓度。 54例患者的子样本中还考虑了脑FDG-PET，其临床诊断与CSF结果不匹配。 结果：高于0.13的p-tau181 /Aβ42比值显示出将AD与OTD区分的最佳诊断性能（准确度指标为86％，灵敏度为74％，特异性为81％）。 在临床诊断和CSF检查之间不匹配的情况下，脑FDG-PET部分符合p-Tu 181/Aβ42比值，从而决定了脑脊液准确性的提高。 结论：单独的p-tau181 /Aβ42比值可以可靠地检测异质性痴呆患者异种样品中的AD病理。 它可能构成一种简单，经济高效且可重现的AD体内替代药物，不仅可以在日常临床实践中使用，而且还可以在以后的实验研究中广泛采用，从而避免招募误诊为AD患者的患者。

关键词: 阿尔茨海默氏病，β淀粉样蛋白42，磷酸化tau蛋白，脑脊液生物标志物，诊断准确性，痴呆。

« Previous Next »
[1]
Karlawish J, Jack CR, Rocca WA, Snyder HM, Carrillo MC. Alzheimer’s disease: the next frontier-Special Report 2017. Alzheimers Dement J Alzheimers Assoc 13(4): 374-80. (2017)
[2]
Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 71(4): 266-73. (2012)
[http://dx.doi.org/10.1097/NEN.0b013e31824b211b] [PMID: 22437338]
[3]
Harris JM, Thompson JC, Gall C, Richardson AMT, Neary D, du Plessis D, et al. Do NIA-AA criteria distinguish Alzheimer’s disease from frontotemporal dementia? Alzheimers Dement 11(2): 207-15. (2015)
[http://dx.doi.org/10.1016/j.jalz.2014.04.516] [PMID: 25022535]
[4]
Fiandaca MS, Mapstone ME, Cheema AK, Federoff HJ. The critical need for defining preclinical biomarkers in Alzheimer’s disease. Alzheimers Dement 10(3): S196-212. (2014)
[http://dx.doi.org/10.1016/j.jalz.2014.04.015] [PMID: 24924671]
[5]
Aisen PS, Cummings J, Jack CR Jr, Morris JC, Sperling R, Frölich L, et al. On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res Ther 9(1): 60. (2017)
[http://dx.doi.org/10.1186/s13195-017-0283-5] [PMID: 28793924]
[6]
Ahmed RM, Paterson RW, Warren JD, Zetterberg H, O’Brien JT, Fox NC, et al. Biomarkers in dementia: clinical utility and new directions. J Neurol Neurosurg Psychiatry 85(12): 1426-34. (2014)
[http://dx.doi.org/10.1136/jnnp-2014-307662] [PMID: 25261571]
[7]
Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol 15(7): 673-84. (2016)
[http://dx.doi.org/10.1016/S1474-4422(16)00070-3] [PMID: 27068280]
[8]
Tapiola T, Alafuzoff I, Herukka S-K, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66(3): 382-9. (2009)
[http://dx.doi.org/10.1001/archneurol.2008.596] [PMID: 19273758]
[9]
Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, et al. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 56(2): 248-53. (2010)
[http://dx.doi.org/10.1373/clinchem.2009.130518] [PMID: 19833838]
[10]
Rivero-Santana A, Ferreira D, Perestelo-Pérez L, Westman E, Wahlund LO, Sarría A, et al. Cerebrospinal fluid biomarkers for the differential diagnosis between Alzheimer’s disease and frontotemporal lobar degeneration: systematic review, HSROC analysis, and confounding factors. J Alzheimers Dis 55(2): 625-44. (2017)
[http://dx.doi.org/10.3233/JAD-160366] [PMID: 27716663]
[11]
Irwin DJ, Trojanowski JQ, Grossman M. Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer’s disease. Front Aging Neurosci 5: 6. (2013)
[http://dx.doi.org/10.3389/fnagi.2013.00006] [PMID: 23440936]
[12]
Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B, et al. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 19(2-3): 164-70. (2005)
[http://dx.doi.org/10.1159/000083178] [PMID: 15637452]
[13]
Ewers M, Mattsson N, Minthon L, Molinuevo JL, Antonell A, Popp J, et al. CSF biomarkers for the differential diagnosis of Alzheimer’s disease: a large-scale international multicenter study. Alzheimers Dement 11(11): 1306-15. (2015)
[http://dx.doi.org/10.1016/j.jalz.2014.12.006] [PMID: 25804998]
[14]
Ritchie C, Smailagic N, Noel-Storr AH, Ukoumunne O, Ladds EC, Martin S. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 3CD010803 (2017)
[http://dx.doi.org/10.1002/14651858.CD010803.pub2] [PMID: 28328043]
[15]
Cummings J. Alzheimer’s disease diagnostic criteria: practical applications. Alzheimers Res Ther 4(5): 35. (2012)
[http://dx.doi.org/10.1186/alzrt138] [PMID: 22947665]
[16]
Josephs KA, Petersen RC, Knopman DS, Boeve BF, Whitwell JL, Duffy JR, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 66(1): 41-8. (2006)
[http://dx.doi.org/10.1212/01.wnl.0000191307.69661.c3] [PMID: 16401843]
[17]
Lippa CF, Smith TW, Swearer JM. Alzheimer’s disease and Lewy body disease: a comparative clinicopathological study. Ann Neurol 35(1): 81-8. (1994)
[http://dx.doi.org/10.1002/ana.410350113] [PMID: 8285597]
[18]
Graff-Radford NR. Alzheimer CSF biomarkers may be misleading in normal-pressure hydrocephalus. Neurology 83(17): 1573-5. (2014)
[http://dx.doi.org/10.1212/WNL.0000000000000916] [PMID: 25332445]
[19]
Levy Nogueira M, Epelbaum S, Steyaert J-M, Dubois B, Schwartz L. Mechanical stress models of Alzheimer’s disease pathology. Alzheimers Dement 12(3): 324-33. (2016)
[http://dx.doi.org/10.1016/j.jalz.2015.10.005] [PMID: 26718585]
[20]
Santangelo R, Cecchetti G, Bernasconi MP, Cardamone R, Barbieri A, Pinto P, et al. Cerebrospinal fluid amyloid-β 42, total tau and phosphorylated tau are low in patients with normal pressure hydrocephalus: analogies and differences with Alzheimer’s disease. J Alzheimers Dis 60(1): 183-200. (2017)
[http://dx.doi.org/10.3233/JAD-170186] [PMID: 28826180]
[21]
Nägga K, Gottfries J, Blennow K, Marcusson J. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer’s disease and vascular dementia. Dement Geriatr Cogn Disord 14(4): 183-90. (2002)
[http://dx.doi.org/10.1159/000066023] [PMID: 12411760]
[22]
Niemantsverdriet E, Feyen BFE, Le Bastard N, Martin JJ, Goeman J, De Deyn PP, et al. Added diagnostic value of cerebrospinal fluid biomarkers for differential dementia diagnosis in an autopsy-confirmed cohort. J Alzheimers Dis 63(1): 373-81. (2018)
[http://dx.doi.org/10.3233/JAD-170927] [PMID: 29614653]
[23]
Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, et al. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer’s disease from other dementias and healthy controls in the OPTIMA cohort. J Alzheimers Dis 44(2): 525-39. (2015)
[http://dx.doi.org/10.3233/JAD-141725] [PMID: 25391385]
[24]
Skillbäck T, Farahmand BY, Rosén C, Mattsson N, Nägga K, Kilander L, et al. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Brain 138(Pt 9): 2716-31. (2015)
[http://dx.doi.org/10.1093/brain/awv181] [PMID: 26133663]
[25]
Bombois S, Duhamel A, Salleron J, Deramecourt V, Mackowiak MA, Deken V, et al. A new decision tree combining Abeta 1-42 and p-Tau levels in Alzheimer’s diagnosis. Curr Alzheimer Res 10(4): 357-64. (2013)
[http://dx.doi.org/10.2174/1567205011310040002] [PMID: 23061918]
[26]
Fourier A, Portelius E, Zetterberg H, Blennow K, Quadrio I, Perret-Liaudet A. Pre-analytical and analytical factors influencing Alzheimer’s disease cerebrospinal fluid biomarker variability. Clin Chim Acta 449: 9-15. (2015)
[http://dx.doi.org/10.1016/j.cca.2015.05.024] [PMID: 26141614]
[27]
Hort J, Bartos A, Pirttilä T, Scheltens P. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Eur J Neurol 17(1): 90-6. (2010)
[http://dx.doi.org/10.1111/j.1468-1331.2009.02753.x] [PMID: 19659752]
[28]
Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer’s disease. Ann Clin Biochem 46(Pt 3): 235-40. (2009)
[http://dx.doi.org/10.1258/acb.2009.008232] [PMID: 19342441]
[29]
Ferreira D, Perestelo-Pérez L, Westman E, Wahlund L-O, Sarría A, Serrano-Aguilar P. Meta-review of CSF core biomarkers in alzheimer’s disease: the state-of-the-art after the new revised diagnostic criteria. Front Aging Neurosci 6: 47. (2014)
[http://dx.doi.org/10.3389/fnagi.2014.00047] [PMID: 24715863]
[30]
Palmqvist S, Hertze J, Minthon L, Wattmo C, Zetterberg H. Blennow Ket al. Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer’s disease in mild cognitive impairment: six-year follow-up study. PLoS One 7(6)e38639 (2012)
[http://dx.doi.org/10.1371/journal.pone.0038639] [PMID: 22761691]
[31]
Perani D, Cerami C, Caminiti SP, Santangelo R, Coppi E, Ferrari L, et al. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting. Eur J Nucl Med Mol Imaging 43(3): 499-508. (2016)
[http://dx.doi.org/10.1007/s00259-015-3170-y] [PMID: 26341365]
[32]
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3): 263-9. (2011)
[http://dx.doi.org/10.1016/j.jalz.2011.03.005] [PMID: 21514250]
[33]
Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134(Pt 9): 2456-77. (2011)
[http://dx.doi.org/10.1093/brain/awr179] [PMID: 21810890]
[34]
Gorno-Tempini ML, Hillis AE, Weintraub S, Mendez MF, Kramer JH, Neuhaus J, et al. Classification of primary progressive aphasia and its variants. Neurology 76(11): 1006-14. (2011)
[http://dx.doi.org/10.1212/WNL.0b013e31821103e6] [PMID: 21325651]
[35]
Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47(1): 1-9. (1996)
[http://dx.doi.org/10.1212/WNL.47.1.1] [PMID: 8710059]
[36]
Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 80(5): 496-503. (2013)
[http://dx.doi.org/10.1212/WNL.0b013e31827f0fd1] [PMID: 23359374]
[37]
McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 89(1): 88-100. (2017)
[http://dx.doi.org/10.1212/WNL.0000000000004058] [PMID: 28592453]
[38]
Erkinjuntti T. Clinical criteria for vascular dementia: the NINDS-AIREN criteria. Dementia 5(3-4): 189-92. (1994)
[PMID: 8087178]
[39]
Marmarou A, Bergsneider M, Relkin N, Klinge P, Black PM. Development of guidelines for idiopathic normal-pressure hydrocephalus: introduction. Neurosurgery 57(3): S1-3. (2005)
[http://dx.doi.org/10.1227/01.NEU.0000168188.25559.0E] [PMID: 16160424]
[40]
Magni E, Binetti G, Bianchetti A, Rozzini R, Trabucchi M. Mini-Mental State Examination: a normative study in Italian elderly population. Eur J Neurol 3(3): 198-202. (1996)
[http://dx.doi.org/10.1111/j.1468-1331.1996.tb00423.x] [PMID: 21284770]
[41]
Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 9(1): 173-6. (1997)
[http://dx.doi.org/10.1017/S1041610297004870] [PMID: 9447441]
[42]
Katz S. Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc 31(12): 721-7. (1983)
[http://dx.doi.org/10.1111/j.1532-5415.1983.tb03391.x] [PMID: 6418786]
[43]
Varrone A, Asenbaum S, Borght TV, Booij J, Nobili F, Någren K, et al. EANM procedure guidelines for PET brain imaging using [<Superscript>18</Superscript>F]FDG, version 2. Eur J Nucl Med Mol Imaging 36(12): 2103. (2009)
[http://dx.doi.org/10.1007/s00259-009-1264-0] [PMID: 19838705]
[44]
Perani D, Della Rosa PA, Cerami C, Gallivanone F, Fallanca F, Vanoli EG, et al. Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. Neuroimage Clin 6: 445-54. (2014)
[http://dx.doi.org/10.1016/j.nicl.2014.10.009] [PMID: 25389519]
[45]
Cerami C, Dodich A, Lettieri G, Iannaccone S, Magnani G, Marcone A, et al. Different FDG-PET metabolic patterns at single-subject level in the behavioral variant of fronto-temporal dementia. Cortex 83: 101-12. (2016)
[http://dx.doi.org/10.1016/j.cortex.2016.07.008] [PMID: 27498041]
[46]
Kalpouzos G, Eustache F, de la Sayette V, Viader F, Chételat G, Desgranges B. Working memory and FDG-PET dissociate early and late onset Alzheimer disease patients. J Neurol 252(5): 548-58. (2005)
[http://dx.doi.org/10.1007/s00415-005-0685-3] [PMID: 15726251]
[47]
Drzezga A, Grimmer T, Henriksen G, Stangier I, Perneczky R, Diehl-Schmid J, et al. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease. Neuroimage 39(2): 619-33. (2008)
[http://dx.doi.org/10.1016/j.neuroimage.2007.09.020] [PMID: 17962045]
[48]
Bousiges O, Cretin B, Lavaux T, Philippi N, Jung B, Hezard S, et al. Diagnostic value of cerebrospinal fluid biomarkers (phospho-Tau181, total-Tau, Aβ42, and Aβ40) in prodromal stage of alzheimer’s disease and dementia with lewy bodies. J Alzheimers Dis 51(4): 1069-83. (2016)
[http://dx.doi.org/10.3233/JAD-150731] [PMID: 26923009]
[49]
Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, et al. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. J Alzheimers Dis 29(1): 229-38. (2012)
[http://dx.doi.org/10.3233/JAD-2011-111349] [PMID: 22232006]
[50]
Schoonenboom NSM, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78(1): 47-54. (2012)
[http://dx.doi.org/10.1212/WNL.0b013e31823ed0f0] [PMID: 22170879]
[51]
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14(4): 535-62. (2018)
[http://dx.doi.org/10.1016/j.jalz.2018.02.018] [PMID: 29653606]
[52]
Abu-Rumeileh S, Giannini G, Polischi B, Albini-Riccioli L, Milletti D, Oppi F, et al. Revisiting the cerebrospinal fluid biomarker profile in idiopathic normal pressure hydrocephalus: the bologna pro-hydro study. J Alzheimers Dis 68(2): 723-33. (2019)
[http://dx.doi.org/10.3233/JAD-181012] [PMID: 30883350]
[53]
Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease. Neurobiol Aging 19(2): 109-16. (1998)
[PMID: 9558143]
[54]
Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 286(17): 2120-7. (2001)
[http://dx.doi.org/10.1001/jama.286.17.2120] [PMID: 11694153]
[55]
Elias A, Woodward M, Rowe CC. Management impact of FDG-PET in dementia: results from a tertiary center memory clinic. J Alzheimers Dis 42(3): 885-92. (2014)
[http://dx.doi.org/10.3233/JAD-132729] [PMID: 24961944]
[56]
Sarikaya I, Sarikaya A, Elgazzar AH. Current status of 18F-FDG PET brain imaging in patients with dementia. J Nucl Med Technol 46(4): 362-7. (2018)
[http://dx.doi.org/10.2967/jnmt.118.210237] [PMID: 30076253]
[57]
Rahimi J, Kovacs GG. Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther 6(9): 82. (2014)
[http://dx.doi.org/10.1186/s13195-014-0082-1] [PMID: 25419243]
[58]
Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N Engl J Med 360(22): 2302-9. (2009)
[http://dx.doi.org/10.1056/NEJMoa0806142] [PMID: 19474427]
[59]
Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 313(19): 1939-49. (2015)
[http://dx.doi.org/10.1001/jama.2015.4669] [PMID: 25988463]
[60]
Ballard C, Ziabreva I, Perry R, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 67(11): 1931-4. (2006)
[http://dx.doi.org/10.1212/01.wnl.0000249130.63615.cc] [PMID: 17159096]
[61]
Howlett DR, Whitfield D, Johnson M, Attems J, O’Brien JT, Aarsland D, et al. Regional multiple pathology scores are associated with cognitive decline in lewy body dementias. Brain Pathol 25(4): 401-8. (2015)
[http://dx.doi.org/10.1111/bpa.12182] [PMID: 25103200]
[62]
Kraybill ML, Larson EB, Tsuang DW, Teri L, McCormick WC, Bowen JD, et al. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 64(12): 2069-73. (2005)
[http://dx.doi.org/10.1212/01.WNL.0000165987.89198.65] [PMID: 15985574]
[63]
Kapaki E, Paraskevas GP, Papageorgiou SG, Bonakis A, Kalfakis N, Zalonis I, et al. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord 22(1): 47-53. (2008)
[http://dx.doi.org/10.1097/WAD.0b013e3181610fea] [PMID: 18317246]
[64]
Schoonenboom NSM, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ, et al. Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 62(9): 1580-4. (2004)
[http://dx.doi.org/10.1212/01.WNL.0000123249.58898.E0] [PMID: 15136685]

Rights & Permissions Print Cite
Article Metrics
49
2
© 2024 Bentham Science Publishers | Privacy Policy